Glatiramer acetate treatment persistence but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)

RESEARCH ARTICLE Open Access Retrospective US database analysis of

Merrikay Oleen-burkey
Anissa Cyhaniuk
Eric Swallow

October 2016

persistence with glatiramer acetate vs. available ies for multiple sclerosis: 15 days or more with a...

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

Daniel R. Wynn

January 2019

Multiple sclerosis (MS) is a chronic progressive neurodegenerative demyelinating disease affecting t...

Examining the Influence of Behavioral Factors on Compliance and Persistence with Glatiramer Acetate Injection for Relapsing-Remitting Multiple Sclerosis

Oleen-Burkey, MerriKay
Pardo, Gabriel
Zwibel, Howard
Denney, Douglas R.

May 2014

Objective: To evaluate the relationship between compliance and persistence with glatiramer acetate (...

Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines

Jongen, P.J.H.
Lemmens, W.A.J.G.
Hupperts, R.
Schrijver, H.M.
Slettenaar, A.
Schryver, E.L.d.
Boringa, J.
Noort, E van
Donders, A.R.T.

January 2016

Contains fulltext : 171162.pdf (publisher's version ) (Open Access

Glatiramer acetate treatment persistence but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: A prospective web-based patient-centred study (CAIR study)

Jongen, Peter Joseph
Lemmens, Wim A.
Hoogervorst, Erwin L.
Donders, Rogier

March 2017

Background: In patients with relapsing remitting multiple sclerosis (RRMS) the persistence of and ad...

Additional file 1: of Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)

Jongen, Sjef
Lemmens, Wim A.
Hoogervorst, Erwin L.
Donders, Rogier
Radboud University Nijmegen Medical Centre

March 2017

Data on adherence, persistence, self-efficacy, HRQoL, gender and disease duration. (XLSX 25 kb

Drug adherence and multidisciplinary care in patients with multiple sclerosis: Protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study)

Jongen, Peter J.
Hengstman, Gerald
Hupperts, Raymond
Schrijver, Hans M.
Gilhuis, Job
Vliegen, Joseph H.
Hoogervorst, Erwin L. J.
van Huizen, Marc
van Munster, Eric
Samijn, Johnny
de Schryver, Els L.
Siepman, Theodora
Tonk, Martijn
Zandbergen, Eveline
ten Holter, Jacques
van der Kruijk, Ruud
Borm, George

March 2011

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous syste...

Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

Jongen, P.J.H.
Hengstman, G.J.D.
Hupperts, R.
Schrijver, H.
Gilhuis, J.
Vliegen, J.H.
Hoogervorst, E.
Huizen, M. van
Munster, E. van
Samijn, J.
Schryver, E. de
Siepman, T.
Tonk, M.
Zandbergen, E.
Holter, J. ten
Kruijk, R. van der
Borm, G.F.

January 2011

BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central n...

Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment:assessment of relationship with care received from multiple disciplines

Jongen, Peter Joseph
Lemmens, Wim A.
Hupperts, Raymond
Hoogervorst, Erwin L. J.
Schrijver, Hans M.
Slettenaar, Astrid
de Schryver, Els L.
Boringa, Jan
van Noort, Esther
Donders, Rogier

January 2016

Background: In multiple sclerosis patients, the persistence of, and adherence to, disease-modifying ...

Glatiramer acetate treatment persistence but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy:A prospective web-based patient-centred study (CAIR study)

Jongen, Peter Joseph
Lemmens, Wim A.
Hoogervorst, Erwin L.
Donders, Rogier

March 2017

Background: In patients with relapsing remitting multiple sclerosis (RRMS) the persistence of and ad...

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.

Filippi, M.
Wolinsky, JS
Comi, G.

January 2006

Item does not contain fulltextBACKGROUND: Parenterally administered glatiramer acetate reduces the f...

Jongen, Peter J.
Lehnick, Dirk
Sanders, Evert
Seeldrayers, Pierette
Fredrikson, Sten
Andersson, Magnus
Speck, Joachim

November 2010

BACKGROUND Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs...

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients

Özlem Taşkapılıoğlu
Aslı Bahar Turan
Murat Albas
Ömer Faruk Turan

March 2012

OBJECTIVE: Glatiramer acetate (GA) has been shown to reduce the number of relapses and improve outco...

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis

Aaron Boster
Mary Pat Bartoszek
Colleen O’Connell
David Pitt
Michael Racke

September 2011

The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA...

The role of glatiramer acetate in the early treatment of multiple sclerosis

David W Brandes

June 2010

David W BrandesHope MS Center, Knoxville, TN, USA; ULCA, Los Angeles, CA, USAAbstract: The treatment...

RESEARCH ARTICLE Open Access Retrospective US database analysis of

Merrikay Oleen-burkey
Anissa Cyhaniuk
Eric Swallow

October 2016

persistence with glatiramer acetate vs. available ies for multiple sclerosis: 15 days or more with a...

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

Daniel R. Wynn

January 2019

Multiple sclerosis (MS) is a chronic progressive neurodegenerative demyelinating disease affecting t...

Examining the Influence of Behavioral Factors on Compliance and Persistence with Glatiramer Acetate Injection for Relapsing-Remitting Multiple Sclerosis

Oleen-Burkey, MerriKay
Pardo, Gabriel
Zwibel, Howard
Denney, Douglas R.

May 2014

Objective: To evaluate the relationship between compliance and persistence with glatiramer acetate (...

Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplines

Jongen, P.J.H.
Lemmens, W.A.J.G.
Hupperts, R.
Schrijver, H.M.
Slettenaar, A.
Schryver, E.L.d.
Boringa, J.
Noort, E van
Donders, A.R.T.

January 2016

Contains fulltext : 171162.pdf (publisher's version ) (Open Access

Glatiramer acetate treatment persistence but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: A prospective web-based patient-centred study (CAIR study)

Jongen, Peter Joseph
Lemmens, Wim A.
Hoogervorst, Erwin L.
Donders, Rogier

March 2017

Background: In patients with relapsing remitting multiple sclerosis (RRMS) the persistence of and ad...

Additional file 1: of Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)

Jongen, Sjef
Lemmens, Wim A.
Hoogervorst, Erwin L.
Donders, Rogier
Radboud University Nijmegen Medical Centre

March 2017

Data on adherence, persistence, self-efficacy, HRQoL, gender and disease duration. (XLSX 25 kb

Drug adherence and multidisciplinary care in patients with multiple sclerosis: Protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study)

Jongen, Peter J.
Hengstman, Gerald
Hupperts, Raymond
Schrijver, Hans M.
Gilhuis, Job
Vliegen, Joseph H.
Hoogervorst, Erwin L. J.
van Huizen, Marc
van Munster, Eric
Samijn, Johnny
de Schryver, Els L.
Siepman, Theodora
Tonk, Martijn
Zandbergen, Eveline
ten Holter, Jacques
van der Kruijk, Ruud
Borm, George

March 2011

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous syste...

Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).

Jongen, P.J.H.
Hengstman, G.J.D.
Hupperts, R.
Schrijver, H.
Gilhuis, J.
Vliegen, J.H.
Hoogervorst, E.
Huizen, M. van
Munster, E. van
Samijn, J.
Schryver, E. de
Siepman, T.
Tonk, M.
Zandbergen, E.
Holter, J. ten
Kruijk, R. van der
Borm, G.F.

January 2011

BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central n...

Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment:assessment of relationship with care received from multiple disciplines

Jongen, Peter Joseph
Lemmens, Wim A.
Hupperts, Raymond
Hoogervorst, Erwin L. J.
Schrijver, Hans M.
Slettenaar, Astrid
de Schryver, Els L.
Boringa, Jan
van Noort, Esther
Donders, Rogier

January 2016

Background: In multiple sclerosis patients, the persistence of, and adherence to, disease-modifying ...

Glatiramer acetate treatment persistence but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy:A prospective web-based patient-centred study (CAIR study)

Jongen, Peter Joseph
Lemmens, Wim A.
Hoogervorst, Erwin L.
Donders, Rogier

March 2017

Background: In patients with relapsing remitting multiple sclerosis (RRMS) the persistence of and ad...

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.

Filippi, M.
Wolinsky, JS
Comi, G.

January 2006

Item does not contain fulltextBACKGROUND: Parenterally administered glatiramer acetate reduces the f...

Jongen, Peter J.
Lehnick, Dirk
Sanders, Evert
Seeldrayers, Pierette
Fredrikson, Sten
Andersson, Magnus
Speck, Joachim

November 2010

BACKGROUND Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs...

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients

Özlem Taşkapılıoğlu
Aslı Bahar Turan
Murat Albas
Ömer Faruk Turan

March 2012

OBJECTIVE: Glatiramer acetate (GA) has been shown to reduce the number of relapses and improve outco...

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis

Aaron Boster
Mary Pat Bartoszek
Colleen O’Connell
David Pitt
Michael Racke

September 2011

The current Multiple Sclerosis (MS) therapeutic landscape is rapidly growing. Glatiramer acetate (GA...

The role of glatiramer acetate in the early treatment of multiple sclerosis

David W Brandes

June 2010

David W BrandesHope MS Center, Knoxville, TN, USA; ULCA, Los Angeles, CA, USAAbstract: The treatment...

RESEARCH ARTICLE Open Access Retrospective US database analysis of

Merrikay Oleen-burkey
Anissa Cyhaniuk
Eric Swallow

October 2016

persistence with glatiramer acetate vs. available ies for multiple sclerosis: 15 days or more with a...

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use

Daniel R. Wynn

January 2019

Multiple sclerosis (MS) is a chronic progressive neurodegenerative demyelinating disease affecting t...

Examining the Influence of Behavioral Factors on Compliance and Persistence with Glatiramer Acetate Injection for Relapsing-Remitting Multiple Sclerosis

Oleen-Burkey, MerriKay
Pardo, Gabriel
Zwibel, Howard
Denney, Douglas R.

May 2014

Objective: To evaluate the relationship between compliance and persistence with glatiramer acetate (...

Glatiramer acetate treatment persistence but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)

Abstract

Extracted data

Glatiramer acetate treatment persistence but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)

Abstract

Extracted data

Related items

Related items